Public Profile

Agios

Agios Pharmaceuticals, often referred to simply as Agios, is a prominent biopharmaceutical company headquartered in the United States. Founded in 2008, Agios has established itself as a leader in the field of metabolic oncology, focusing on the discovery and development of innovative therapies for cancer and rare genetic diseases. With a strong emphasis on precision medicine, Agios has made significant strides in developing unique small molecule drugs that target specific metabolic pathways. Their flagship products, including therapies for acute myeloid leukaemia and hereditary cancer syndromes, highlight the company's commitment to addressing unmet medical needs. Recognised for its pioneering research and development efforts, Agios continues to solidify its market position through strategic partnerships and a robust pipeline of potential treatments, making it a key player in the biopharmaceutical landscape.

DitchCarbon Score

How does Agios's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Agios's score of 20 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.

76%

Let us know if this data was useful to you

Agios's reported carbon emissions

Agios, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of detailed information, it is essential to monitor Agios's future disclosures regarding their climate commitments and any potential strategies they may implement to reduce their environmental impact.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Agios's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Agios is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Agios is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

BioMarin

US
Chemicals nec
Updated 5 days ago

Bristol-Myers Squibb

US
Pharmaceutical Preparation Manufacturing
Updated about 24 hours ago

Novartis International AG

CH
Real estate services (70)
Updated 6 days ago
DitchCarbon Score

Vertex Pharmaceuticals

US
Research and development services (73)
Updated 5 days ago

Incyte

US
Health and social work services (85)
Updated 5 days ago

PharmaEssentia USA Corporation

US
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers